Immunotherapy drugs when combined prevent melanoma progression

In a new trial, researchers have discovered that a combination of 2 immunotherapy drugs-ipilimumab and nivolumab- is capable of reversing or preventing the progression of advanced melanoma for 5 years or more in every 2 patients.

Just 10 years ago, only 1 in 20 patients with advanced melanoma would survive for 5 years- with many living for just 6-9 months.

The results of the trial,  represent the longest phase 3 trial follow-up for checkpoint inhibitor combination therapy.

In the past, metastatic melanoma was regarded as untreatable. Oncologists considered melanoma different to other cancers-- it couldn't be treated once it had spread. This is the first time we can say that the chances of being a long-term survivor of advanced melanoma are now over 50%, said one of the researcher.

Researchers incorporated 945 patients with advanced melanoma randomised into 3 groups- 314 patients received the ' double-hit' of nivolumab + ipilimumab; 316 patients received nivolumab + a placebo; and 315 patients received ipilimumab + placebo.

Each nivolumab arm was compared to ipilimumab by itself, and was administered until the disease progressed or until any side-effects became unacceptable.

The 5 year overall survival rate for the combination of nivolumab + ipilimumab was 52 %, with 74 % of those patients treatment-free after 5 years. The overall survival for nivolumab was 44 % and 26% for ipilimumab.

The Prof. explained, by giving these drugs together you're effectively taking 2 brakes off the immune system rather than one so that the immune system is able to recognise tumours it wasn't previously recognising and react to that and destroy them.

Importantly, for those patients who stopped treatment because of side-effects such as fatigue, skin rashes and diarrhea, the outcome was just as good as it was for those who were on the combination for longer.

One of the key points about immunotherapies is that the immune system can be re-educated even with a short duration of treatment. This is in contrast to other treatments like chemotherapy which can require a full course to be as effective.

 this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   
https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement   

This immunotherapy combination shrinks rare, neuroendocrine

According to a new research, there is a significant clinical benefit for patients with high-grade neuroendocrine carcinoma, which is the cancer of the neuroendocrine cells that often form tumours in the lungs and along the digestive tract too.

Even though, this cancer is rare, about 12,000 people in the United States are diagnosed with it, every year. But, do you know that the general prevalence of the disease grew six-fold between 1973 and 2012? Patients with the high-grade, or rapidly growing, form have tend to have only few treatment options.

“We saw a benefit in patients with high-grade carcinoma, which is the population that really needs an effective treatment option,” said a Dr. These early results are really encouraging and intriguing. We found a clear difference in response to treatment between the high-grade and low-grade forms of this cancer type,” said the Dr.”So tumour biology makes a difference. We don`t yet know why, but we`ve opened another treatment arm of the trial to patients with just high-grade neuroendocrine carcinoma to see if we find the same response to the immunotherapy combination,” the Dr. added.

DART features an innovative ‘basket’ design which allows the testing of a single drug or drug combination in a variety of tumour types. DART, currently tests the immunotherapy combination of ipilimumab and nivolumab in patients with 37 types of rare cancers, which together make up almost a quarter of all cancers diagnosed worldwide.

Researchers enrolled 33 patients with neuroendocrine tumours. Of those 33 patients, 19 had high-grade disease. Most patients’ tumours were located in the gastrointestinal tract or the lungs. All patients received doses of ipilimumab every six weeks and doses of nivolumab every two weeks and continue on the treatment for as long as their bodies respond to the drugs. Results showed that 42 per cent of patients with the high-grade form of neuroendocrine carcinomas saw their tumours shrink partially or completely after treatment, while none of the low-grade patients did. For all the patients, 70 per cent saw their cancer spread within six months.

Patients survived a median of at least 11 months after treatment. Some patients are alive more than a year after treatment, and doctors continue to track their progress.”There’s a myth that you can’t successfully complete clinical trials in rare cancers. Researchers think it’s too hard to find patients. But DART shows us that we can run rare cancer trials, and enroll patients quickly and learn if therapies are effective in rare diseases,” he said.”We can also offer investigational drugs to patients’ right in their communities. They don’t necessarily need to travel to a cancer centre to get enrolled in a clinical trial.”

THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.                                    PS- THOSE INTERESTED IN RECIPES ARE FREE TO  VIEW MY BLOG-                                                                                           https://gseasyrecipes.blogspot.com/                                                                                                                                                         FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG-                                                  https:// kneereplacement-stickclub.blogspot.com/           

                   FOR CROCHET DESIGNS                                                                                                                                                                                                  https://gscrochetdesigns.blogspot.com

Promising therapies that can help battle this terminal illness

THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOUR PHYSICIAN BEFORE HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.

PS- THOSE INTERESTED IN RECIPES ARE FREE TO VIEW MY BLOG-
HTTP:GSEASYRECIPES.BLOGSPOT.COM      

FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG

HTTP://KNEE REPLACEMENT-STICK CLUB.BLOGSPOT.COM/

FOR CROCHET DESIGNS- http://My Crochet Creations.blogspot.com/


Going through cancer treatment and surviving cancer is an arduous journey.

With the evolution of medicine, researchers and scientists have been able to find several ways to deter cancer cells from spreading. But, across the world scientists are still struggling to find foolproof ways of prevention and medication that can cure the fatal disease.

While the disease in itself is fatal, treatment for cancer is painful as well. Harsh drugs, radiation and chemotherapy often leave patients' health in a fragile state. And as newer ways of battling cancer are being introduced, on World Cancer Day, we look at what researchers suggest are promising treatments for the disease:

Representational image.

Adoptive T-cell Therapy: Thymocyte cells or T-lymphocytes are a type of lymphocyte play a key role in immunity. And researchers at the UW School of Medicine say that, "Adoptive T-cell therapy (helps) achieve greater number of T cells than what could be obtained by vaccination alone. The tumor specific T cells are then infused into patients with cancer in an attempt to give their immune system the ability to overwhelm remaining tumor."
According to the researchers, there are several types of T-cell therapy that are being developed that include engineering cells that identify and attack tumours.
Nature says that while T-cell engineering is a cause for optimism, development of more potent T-cells have been stopped by safety concerns.
Immune checkpoint inhibitors: It is when our immune system cannot distinguish between cancer and normal cells is when cancer cells grow. And one way to stop the growth of cancer cells is to use drugs that hide from the "checkpoints" the immune system uses to separate normal cells from foreign cells.
According to cancer.org, antibodies like Pembrolizumab, Nivolumab and Ipilimumab help treat certain types of cancers. The research states that such therapy has shown to have helped cancers like melanoma and non-small cell lung cancer.
Targeted therapy: It targets the changes in cancer cells, the way the divide and spread. According to cancer.gov there are two types of targeted therapy that are done with the use of small-molecule drugs and monoclonal antibodies. The first one is used for targets that are inside cells while the second one attaches itself on the outside of the target.
According to research, this treatment helps destroy cancer cells, stop them from growing, kills them and starve them of hormones that they need to grow.
Hormone therapy with Goserlin: breastcancercare.org states that this drug can be used to treat "women whose breast cancer is sensitive to the female hormone oestrogen – known as oestrogen receptor positive or ER+ breast cancer." It is administered through subcutaneous injections and the frequency depends on the severity of the cancer.
Goserlin uses ovarian suppression or the switching off of production of Oestrogen, since some cancer cells use Oestrogen to grow.